Fischer Medical Ventures Ltd has informed the exchange on the outcome of Board meeting
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Fischer Medical Ventures Ltd approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with the statutory auditor (M/s. Bilimoria Mehta & Co.) issuing an unmodified (clean) opinion. Consolidated revenue from operations surged to Rs. 11,069.87 lakhs in FY25 from Rs. 2,098.13 lakhs in FY24, while consolidated profit after tax fell to Rs. 120.79 lakhs from Rs. 183.79 lakhs, dragged by higher expenses and share of losses from associates. Standalone revenue declined sharply to Rs. 521.97 lakhs (from Rs. 1,152.83 lakhs), though standalone PAT improved to Rs. 66.32 lakhs from Rs. 40.28 lakhs. The Board recommended a final dividend of Rs. 0.05 per equity share, re-appointed the statutory auditor for a second five-year term, appointed a new internal auditor, and recommended listing of shares on the NSE main board.
The explosive consolidated revenue growth signals aggressive business expansion (backed by ~Rs. 25,000 lakhs raised via share issuances and investments into multiple new subsidiaries), but the PAT decline and negative standalone operating cash flow (-Rs. 2,280.64 lakhs) suggest the company is in a heavy investment phase with profitability yet to scale. The nominal dividend and continued losses from associates are mildly negative, while the proposed NSE listing could improve liquidity and visibility for shareholders.